Furthermore, we investigated the variant SFXN3 expression in M3 and non-M3 AML patients and found that SFXN3 was preferentially overexpressed in non-M3 AML patients (8.02 ± 8.20) than in M3 patients (2.17 ± 1.12) (p < 0.05) and volunteers (1.08 ± 0.43) (p < 0.01). Here, SFXN3 is linked to acute myeloid leukemia.